Vraylar (cariprazine) Letter of Medical Necessity
Vraylar (cariprazine) is commonly denied via step-therapy requirements that mandate two generic atypical antipsychotic trials. Letters of Medical Necessity documenting prior failures, intolerance, or specific receptor-binding rationale (D3 preference) support exception requests.
FDA-Approved Indications
- ● schizophrenia
- ● acute manic or mixed episodes of bipolar I disorder
- ● depressive episodes of bipolar I disorder
- ● adjunctive treatment of major depressive disorder
Why Vraylar Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: two generic atypical antipsychotics not tried
- 2. Diagnosis ICD-10 specificity insufficient
- 3. Adjunctive MDD use without documented antidepressant trials
- 4. Quantity limit (mg/day) exceeded
- 5. Drug-drug interaction with strong CYP3A4 inhibitor not addressed
What to Include in a Vraylar Letter of Medical Necessity
Document the DSM-5 diagnosis with ICD-10 specificity, severity (PHQ-9, MADRS, YMRS, or PANSS as appropriate), prior antipsychotic trials with dates and reasons for discontinuation (efficacy, EPS, weight gain, metabolic effects, prolactin elevation), current concomitant medications (especially CYP3A4 inhibitors), and rationale for cariprazine — particularly its lower metabolic burden vs olanzapine/quetiapine and partial-agonist profile vs full antagonists.
Key clinical evidence to cite:
- ✓ Schizophrenia Phase 3 trials (RGH-MD-04, RGH-MD-05, RGH-MD-16)
- ✓ Bipolar mania trials (RGH-MD-31, RGH-MD-32)
- ✓ Bipolar depression trials (RGH-MD-56, RGH-MD-58)
- ✓ MDD adjunctive trials (3111-301-001, 3111-302-001)
Relevant guidelines:
- 📖 APA Practice Guideline for Schizophrenia (2020)
- 📖 CANMAT 2018 Bipolar Guidelines
- 📖 APA MDD Treatment Guidelines
Vraylar Prior Authorization Criteria
Standard criteria across major US payers for Vraylar. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: two generic atypical antipsychotics not tried
- → Adjunctive MDD use without documented antidepressant trials
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Vraylar
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Vraylar Prior Authorization FAQ
Why was my Vraylar prior authorization denied?
The most common denial reasons for Vraylar are: Step therapy: two generic atypical antipsychotics not tried; Diagnosis ICD-10 specificity insufficient; Adjunctive MDD use without documented antidepressant trials; Quantity limit (mg/day) exceeded; Drug-drug interaction with strong CYP3A4 inhibitor not addressed.
What should a Vraylar Letter of Medical Necessity include?
Document the DSM-5 diagnosis with ICD-10 specificity, severity (PHQ-9, MADRS, YMRS, or PANSS as appropriate), prior antipsychotic trials with dates and reasons for discontinuation (efficacy, EPS, weight gain, metabolic effects, prolactin elevation), current concomitant medications (especially CYP3A4 inhibitors), and rationale for cariprazine — particularly its lower metabolic burden vs olanzapine/quetiapine and partial-agonist profile vs full antagonists.
Which payers cover Vraylar?
Vraylar is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.